Valneva (NASDAQ:VALN) Shares Gap Down to $7.92

Valneva SE (NASDAQ:VALN - Get Free Report) gapped down prior to trading on Monday . The stock had previously closed at $7.92, but opened at $7.76. Valneva shares last traded at $7.76, with a volume of 234 shares trading hands.

Analyst Ratings Changes

A number of analysts have issued reports on the stock. HC Wainwright reiterated a "buy" rating and issued a $26.00 target price on shares of Valneva in a research note on Thursday, March 21st. Guggenheim dropped their price target on shares of Valneva from $18.00 to $17.00 and set a "buy" rating on the stock in a research report on Friday, March 22nd.

Valneva Stock Performance

The company has a market cap of $532.76 million, a P/E ratio of -4.85 and a beta of 2.25. The company has a quick ratio of 1.37, a current ratio of 1.65 and a debt-to-equity ratio of 1.04. The stock's 50-day moving average price is $7.68 and its 200 day moving average price is $10.01.

Hedge Funds Weigh In On Valneva

A number of institutional investors and hedge funds have recently bought and sold shares of VALN. Jane Street Group LLC increased its position in Valneva by 85.9% during the first quarter. Jane Street Group LLC now owns 16,584 shares of the company's stock worth $569,000 after acquiring an additional 7,664 shares during the period. Bank of America Corp DE bought a new position in Valneva during the first quarter worth $858,000. Finally, UBS Group AG bought a new position in Valneva during the second quarter worth $31,000. Institutional investors own 11.39% of the company's stock.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.